PV Bulletin

Class 4 Defect Notification: Cadila Mirtazapine 30mg Tablets (EL(26)A/28)

Quality defect notification for Mirtazapine 30mg Tablets by Cadila Pharmaceuticals Limited; healthcare professionals to check affected batches.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

MHRA published a Class 4 defect notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals).

Why it matters

Product quality defect may affect patient safety; requires batch checking and potential product recall actions.

Action needed

Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

immediate

Regulatory action details

Action type
Medicines Defect Notification (Class 4)
Publication date
2026-06-08
Safety issue
Quality defect notification for Mirtazapine 30mg Tablets manufactured by Cadila Pharmaceuticals Limited.

Affected products

  • Mirtazapine 30mg Tablets
    Cadila Pharmaceuticals Limited

PV internal implications

Healthcare professionals should check for the affected batches and note the defect as described in EL(26)A/28.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 8, 2026

Full briefing

Practical implication

Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.

MHRA issued a Class 4 Medicines Defect Notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals Limited) on 8 June 2026. Healthcare professionals should identify affected batches and note the defect per EL(26)A/28.

What changed: MHRA published a Class 4 defect notification for Mirtazapine 30mg Tablets (Cadila Pharmaceuticals).

Why it matters: Product quality defect may affect patient safety; requires batch checking and potential product recall actions.

Practical implication: Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#Medicines Defect Notification (Class 4)#Medicines and Healthcare products Regulatory Agency (MHRA)#other#firecrawl-agent#regulatory-extraction

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward